1. Pink Sheet
  2. >>Market Access

EU HTA Regulation: Companies Can Talk To National Authorities As ‘Substitute’ For EU-Level Advice

 
• By Eliza Slawther

Not all companies will be able to access joint scientific consultations under the EU Health Technology Assessment Regulation, but success is still possible for those that engage with national agencies early on, says EUCOPE’s Alexander Natz.

Stefano Benvenuti, Henriette Burghoorn, Paolo Morgese, Marcus Droege, Stijn Heessen and Alexander Natz at the Advanced Therapies Congress in London, 2025 (Norstella)

Alexander Natz, secretary general of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), is “optimistic” that the EU Health Technology Assessment (HTA) Regulation will be a positive step, particularly for advanced therapies intended to treat ultra-rare diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Rare Diseases